Undisclosed Anti-Inflammatory Therapeutic / Biogen - LARVOL DELTA

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. (GlobeNewswire) - "...Biogen has agreed to acquire RayThera Inc. for up to $1 billion, consisting of an upfront payment and, predominantly, payments contingent on the achievement of future clinical and regulatory milestones...RayThera’s portfolio includes multiple anti-inflammatory assets that could potentially treat immune-mediated conditions across a range of indications. The lead candidate is expected to enter Phase 1 development in early Q3 2026....The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals and is currently anticipated to close in the third quarter of 2026."

M&A • New P1 trial • Immunology • Inflammation